Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 32, Issue 3-4, 1999, Pages 279-288

  Bachier, Carlos R ^a   Giles, Richard E ^b   Ellerson, Deborah ^b   Hanania, Ellie G ^b   Garcia Sanchez, Felix ^b   Andreeff, Michael ^b   Cabanillas, Fernando ^b   Champlin, Richard ^b   Choudhury, Raja ^b   Berenson, Ronald ^b   Heimfeld, Shelly ^b   Deisseroth, Albert B ^b  

^a South Texas Cancer Institute   (United States)

^b NONE

Author keywords

Follicular non Hodgkin's lymphoma; Hematopietic gene marking; Retroviral gene marking

Indexed keywords

CD19 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CASE REPORT; CELL CULTURE; FOLLICULAR LYMPHOMA; HEMATOPOIESIS; HUMAN; MONONUCLEAR CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROVIRUS; SOUTHERN BLOTTING; STEM CELL TRANSPLANTATION; VIRUS GENE; WHOLE BODY RADIATION;

EID: 0033021495     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909167388     Document Type: Article

References (18)

1. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Odeal P, Romaguera JE, Rodriguez MA, Redman JR, Keating M: Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:3, 1994.
2. Solal-Celigny P, Brice P, Brousse N, Caspard H, Bastion Y, Hauion C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau JL, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Leporrier M: Phase II trial of fludarabine monophosphate as first line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe D'Etude des Lymphomes de l'Adulte. J Clin Oncol 14: 2, 1996.
3. Tefferi A, Witzig TE, Reid JL, Li CY, Ames MM: Phase I study of Combined 2-Chlorodeoxyadenosine and Chlorambucil in Chronic Lymphocytic Leukemia and low grade lymphoma. J Clin Oncol 12: 3, 1994.
4. Maloney DG, Grillo-Lopez AJ, Bodkin D, White C, Foon K, Schilder RJ, Neidhart J, Janakiraman N, Waldichuk C, Davis T, Dallaire BK, Royston I, Levy R: IDEC C2B8 Anti-CD20 Antibody: Result of long-term follow-up of relapsed NHL phase II trial patients. Blood 86(10): 54a, 1995.
5. Cabanillas F, Grillo-Lopez AJ, Mclaughlin P, Link BK, Levy R, Czuczman M, Heyman MR, Williams M, Jain V, Bence-Bruckler, Ho AD, Lister J, Rogers J, Shen D, Varns C: Anti - CD20 Antibody (MAB), IDEC-C2B8: Clearance of bcl-2 t(14:18) positive cells from peripheral blood and bone marrow in patients with relapsed low-grade or follicular lymphoma. Blood 88(10): 91a, 1996
6. Freedman AS, Ritz J, Neuberg D Anderson KC, Rabinowe SN, Mauch P, Takvorian T, Soiffer R, Blake K, Yeap B, Coral F, Helfin L, Nadler LM: Autologous bone marrow transplantation in 69 patients with a history of low grade B cell non-Hodgkin's lymphoma. Blood 77: 2524, 1991.
7. Rohatiner A, Johnson P, Price C, Amott SJ, Norton A, Dorey E, Adams K, Whelan J, Matthews J, MacCallum P, Oza A, Lister T: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12: 1177, 1994.
8. Colombat P, Donadio D, Fouillard L, Milpied N, Tilly H, Pico J, Abrgrall H, Coiffier B, Herbrecht T, Philip T: Value of autologous bone marrow transplantation in follicular lymphoma: A France Autogreffe retrospective study of 41 patients. Bone Marrow Transplant 13: 157, 1994
9. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM: High dose therapy and autologous bone marrow transplantation in patient with follicular lymphoma during first remission. Blood 88: 7, 1996.
10. Gribben J, Neuberg D, Freedman A, Gimmi C, Pesek K, Barber M, Saporito L, Woo S, Coral F, Spector N, Rabinowe S, Grossbard B, Ritz J, Nadler L: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81: 3449, 1993.
11. Deisseroth AB, Zu Z, Claxton E, Hanania Eg, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson F, Hester J, Korbling M, Durett, Moen R, Berenson R, Heimfeld S, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantarjian H, Champlin R, Reading C: Genetic Marking shows that Ph+ cells present in autologous transplants of Chronic Myelogenous Leukemia contribute to relapse after autologous bone marrow in CML. Blood 83: 10, 1994.
12. Brenner MK, Rill DR, Holloday MS, Heslop HS, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle J: Gene marking to determine whether autologous marrow infusion restores long term hematopoiesis in cancer patients. Lancet 342: 1134, 1993.
13. Brenner MK, Rill DR, Moen RC, Holloday MS, Heslop HS, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle J: Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341: 8, 1993.
14. Brenner MK, Rill DR, Moen RC, Holloday MS, Heslop HS, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle J: Autologous bone marrow transplant for children with AML in first complete remission: Use of marker genes to investigate the biology of marrow reconstitution and the mechanism of relapse. Human Gene Therapy 2: 137, 1991.
15. Dunbar CE, Cotler FM, O'Shaghnessy JA: Retrovirally marked CD 34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 85: 3048, 1995.
16. Lambrechts AC, Hupkes PE, Dorssers LCJ, van't Veer MB: Clinical significance of translocation t(14;18) positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. J Clin Oncol 12: 1541, 1994.
17. Price CGA, Meerabux J, Murtagh S, Cotter FE, Rohatiner AZ, Young BD, Lister TA: The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Onco 9: 1527, 1991.
18. H rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 14: 1333, 1996.